The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ipilimumab for advanced, refractory melanoma: A report of the Israeli cohort of expanded access program.
Ronnie Shapira-Frommer
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Frank Stephen
No relevant relationships to disclose
Eytan Ben-Ami
No relevant relationships to disclose
Tamar Hamburger
No relevant relationships to disclose
Gal Markel
No relevant relationships to disclose
Inna Ospovat
No relevant relationships to disclose
Douglas Zippel
No relevant relationships to disclose
Sharon Merims
No relevant relationships to disclose
Sara Apter
No relevant relationships to disclose
Hani Steinberg
No relevant relationships to disclose
Yael Silman-Steiberg
No relevant relationships to disclose
Tamar Peretz
No relevant relationships to disclose
Michal Lotem
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Jacob Schachter
Consultant or Advisory Role - Bristol-Myers Squibb